Skip to main content

Deep brain stimulation may reduce the relative risk of clinically important worsening in early stage Parkinson's disease.


AUTHORS

Hacker ML , Tonascia J , Turchan M , Currie A , Heusinkveld L , Konrad PE , Davis TL , Neimat JS , Phibbs FT , Hedera P , Wang L , Shi Y , Shade DM , Sternberg AL , Drye LT , Charles D , . Parkinsonism & related disorders. 2015 8 11; ().

ABSTRACT

The Vanderbilt pilot trial of deep brain stimulation (DBS) in early Parkinson’s disease (PD) enrolled patients on medications six months to four years without motor fluctuations or dyskinesias. We conducted a patient-centered analysis based on clinically important worsening of motor symptoms and complications of medical therapy for all subjects and a subset of subjects with a more focused medication duration. Continuous outcomes were also analyzed for this focused cohort.


The Vanderbilt pilot trial of deep brain stimulation (DBS) in early Parkinson’s disease (PD) enrolled patients on medications six months to four years without motor fluctuations or dyskinesias. We conducted a patient-centered analysis based on clinically important worsening of motor symptoms and complications of medical therapy for all subjects and a subset of subjects with a more focused medication duration. Continuous outcomes were also analyzed for this focused cohort.


Tags: